Older women with localized breast cancer: Costs and survival rates increased across two time periods

Aaron J. Feinstein, Jessica Long, Pamela R. Soulos, Xiaomei Ma, Jeph Herrin, Kevin Frick, Anees B. Chagpar, Harlan M. Krumholz, James B. Yu, Joseph S. Ross, Cary P. Gross

Research output: Contribution to journalArticle

Abstract

Significant national attention has been paid to the rising costs of cancer care. However, few studies have evaluated the association between trends in costs and survival outcomes. We used the Surveillance, Epidemiology, and End Results (SEER) Program-Medicare linked database to compare changes in costs and survival rates over time, among women ages 67-94 who were diagnosed with stage II or III breast cancer in 1994-96 or 2004-06.We found that median cancer-related costs increased from $12,335 to $17,396 among women with stage II disease, and from $18,107 to $32,598 among women with stage III disease. Although the median cost of breast surgery declined between the two study periods, the median cost of chemo- and radiation therapy increased substantially, leading to an overall rise in cancer-related costs. Meanwhile, adjusted overall five-year survival improved, from 67.8 percent to 72.5 percent for women with stage II disease and from 38.5 percent to 51.9 percent for those with stage III disease. These findings suggest that increases in cancer care costs have been accompanied by improved outcomes. Future work should identify opportunities to optimize efficiency in cancer care.

Original languageEnglish (US)
Pages (from-to)592-600
Number of pages9
JournalHealth Affairs
Volume34
Issue number4
DOIs
StatePublished - 2015

Fingerprint

Survival Rate
Breast Neoplasms
Costs and Cost Analysis
Neoplasms
SEER Program
Survival
Medicare
Breast
Radiotherapy
Databases

ASJC Scopus subject areas

  • Health Policy

Cite this

Older women with localized breast cancer : Costs and survival rates increased across two time periods. / Feinstein, Aaron J.; Long, Jessica; Soulos, Pamela R.; Ma, Xiaomei; Herrin, Jeph; Frick, Kevin; Chagpar, Anees B.; Krumholz, Harlan M.; Yu, James B.; Ross, Joseph S.; Gross, Cary P.

In: Health Affairs, Vol. 34, No. 4, 2015, p. 592-600.

Research output: Contribution to journalArticle

Feinstein, AJ, Long, J, Soulos, PR, Ma, X, Herrin, J, Frick, K, Chagpar, AB, Krumholz, HM, Yu, JB, Ross, JS & Gross, CP 2015, 'Older women with localized breast cancer: Costs and survival rates increased across two time periods', Health Affairs, vol. 34, no. 4, pp. 592-600. https://doi.org/10.1377/hlthaff.2014.1119
Feinstein, Aaron J. ; Long, Jessica ; Soulos, Pamela R. ; Ma, Xiaomei ; Herrin, Jeph ; Frick, Kevin ; Chagpar, Anees B. ; Krumholz, Harlan M. ; Yu, James B. ; Ross, Joseph S. ; Gross, Cary P. / Older women with localized breast cancer : Costs and survival rates increased across two time periods. In: Health Affairs. 2015 ; Vol. 34, No. 4. pp. 592-600.
@article{3b58f449eb9448669166cc6eead035ca,
title = "Older women with localized breast cancer: Costs and survival rates increased across two time periods",
abstract = "Significant national attention has been paid to the rising costs of cancer care. However, few studies have evaluated the association between trends in costs and survival outcomes. We used the Surveillance, Epidemiology, and End Results (SEER) Program-Medicare linked database to compare changes in costs and survival rates over time, among women ages 67-94 who were diagnosed with stage II or III breast cancer in 1994-96 or 2004-06.We found that median cancer-related costs increased from $12,335 to $17,396 among women with stage II disease, and from $18,107 to $32,598 among women with stage III disease. Although the median cost of breast surgery declined between the two study periods, the median cost of chemo- and radiation therapy increased substantially, leading to an overall rise in cancer-related costs. Meanwhile, adjusted overall five-year survival improved, from 67.8 percent to 72.5 percent for women with stage II disease and from 38.5 percent to 51.9 percent for those with stage III disease. These findings suggest that increases in cancer care costs have been accompanied by improved outcomes. Future work should identify opportunities to optimize efficiency in cancer care.",
author = "Feinstein, {Aaron J.} and Jessica Long and Soulos, {Pamela R.} and Xiaomei Ma and Jeph Herrin and Kevin Frick and Chagpar, {Anees B.} and Krumholz, {Harlan M.} and Yu, {James B.} and Ross, {Joseph S.} and Gross, {Cary P.}",
year = "2015",
doi = "10.1377/hlthaff.2014.1119",
language = "English (US)",
volume = "34",
pages = "592--600",
journal = "Health Affairs",
issn = "0278-2715",
publisher = "Project Hope",
number = "4",

}

TY - JOUR

T1 - Older women with localized breast cancer

T2 - Costs and survival rates increased across two time periods

AU - Feinstein, Aaron J.

AU - Long, Jessica

AU - Soulos, Pamela R.

AU - Ma, Xiaomei

AU - Herrin, Jeph

AU - Frick, Kevin

AU - Chagpar, Anees B.

AU - Krumholz, Harlan M.

AU - Yu, James B.

AU - Ross, Joseph S.

AU - Gross, Cary P.

PY - 2015

Y1 - 2015

N2 - Significant national attention has been paid to the rising costs of cancer care. However, few studies have evaluated the association between trends in costs and survival outcomes. We used the Surveillance, Epidemiology, and End Results (SEER) Program-Medicare linked database to compare changes in costs and survival rates over time, among women ages 67-94 who were diagnosed with stage II or III breast cancer in 1994-96 or 2004-06.We found that median cancer-related costs increased from $12,335 to $17,396 among women with stage II disease, and from $18,107 to $32,598 among women with stage III disease. Although the median cost of breast surgery declined between the two study periods, the median cost of chemo- and radiation therapy increased substantially, leading to an overall rise in cancer-related costs. Meanwhile, adjusted overall five-year survival improved, from 67.8 percent to 72.5 percent for women with stage II disease and from 38.5 percent to 51.9 percent for those with stage III disease. These findings suggest that increases in cancer care costs have been accompanied by improved outcomes. Future work should identify opportunities to optimize efficiency in cancer care.

AB - Significant national attention has been paid to the rising costs of cancer care. However, few studies have evaluated the association between trends in costs and survival outcomes. We used the Surveillance, Epidemiology, and End Results (SEER) Program-Medicare linked database to compare changes in costs and survival rates over time, among women ages 67-94 who were diagnosed with stage II or III breast cancer in 1994-96 or 2004-06.We found that median cancer-related costs increased from $12,335 to $17,396 among women with stage II disease, and from $18,107 to $32,598 among women with stage III disease. Although the median cost of breast surgery declined between the two study periods, the median cost of chemo- and radiation therapy increased substantially, leading to an overall rise in cancer-related costs. Meanwhile, adjusted overall five-year survival improved, from 67.8 percent to 72.5 percent for women with stage II disease and from 38.5 percent to 51.9 percent for those with stage III disease. These findings suggest that increases in cancer care costs have been accompanied by improved outcomes. Future work should identify opportunities to optimize efficiency in cancer care.

UR - http://www.scopus.com/inward/record.url?scp=84929615808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929615808&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.2014.1119

DO - 10.1377/hlthaff.2014.1119

M3 - Article

C2 - 25847641

AN - SCOPUS:84929615808

VL - 34

SP - 592

EP - 600

JO - Health Affairs

JF - Health Affairs

SN - 0278-2715

IS - 4

ER -